Post

Patient Preference Information in Medical Device Development and Benefit-Risk Assessments (DRAFT)

This guidance provides recommendations on incorporating voluntary Patient Preference Information (PPI) throughout the total product lifecycle of medical devices. It focuses on how PPI may be considered by FDA in decision-making, outlines qualities of valid patient preference studies, provides practical recommendations for collecting and submitting PPI, and discusses inclusion of PPI in decision summaries and device labeling.

This is a draft guidance. Not for implementation.

  1. Engage early with FDA during PPI study planning and design
  2. Conduct qualitative research to inform quantitative PPI study design
  3. Pre-test survey instruments and communication formats with target population
  4. Ensure study population is representative of intended device users
  5. Document study methodology, including statistical analysis plan
  6. Include comprehensive data quality checks and validation
  7. Submit complete study information to FDA including:
    • Scientific question and objectives
    • Study design and methods
    • Eligibility criteria and recruitment approach
    • Survey instrument design
    • Results with demographics
  8. Incorporate PPI findings appropriately in device labeling
  9. Follow established good research practices from recognized organizations
  10. Maintain data integrity throughout the study process

Key Considerations

Non-clinical testing

  • Patient input can inform device design and features during discovery and ideation phase
  • Patient-sensitive design inputs may help refine device design to better meet patient end-user needs

Human Factors

  • Studies should ensure patient comprehension with minimal cognitive bias
  • Pre-testing of communication formats and survey instruments recommended
  • Study design should minimize potential cognitive biases

Labeling

  • Patient labeling should be written in plain language
  • Visual aids like pictorials, graphics, or tables should be included when appropriate
  • Clear statement about intended population required
  • Information about benefits, risks, contraindications, warnings and precautions should be included
  • Likelihoods of benefits and risks should be expressed in absolute terms

Safety

  • Critical aspects of benefit, risk and uncertainty should be included in preference elicitation
  • Risk attributes descriptions should appropriately convey severity and impact
  • Study should measure preferences of representative sample to generalize to population

Other considerations

  • 21 CFR Parts 50, 56, and 812: Protection of Human Subjects, Institutional Review Boards, Investigational Device Exemptions
  • 21 CFR Parts 801 and 809: Labeling Requirements
  • 21 CFR 860.7: Determination of Safety and Effectiveness

Original guidance

  • Patient Preference Information in Medical Device Development and Benefit-Risk Assessments
  • HTML / PDF
  • Issue date: 2024-09-06
  • Last changed date: 2024-09-09
  • Status: DRAFT
  • Official FDA topics: Medical Devices, Biologics
  • ReguVirta summary file ID: ca6d21e5d3c66ae4d49e9669b651a1ff
This post is licensed under CC BY 4.0 by the author.